000289304 001__ 289304
000289304 005__ 20240906161535.0
000289304 0247_ $$2doi$$a10.1093/neuonc/noae071
000289304 0247_ $$2pmid$$apmid:38578306
000289304 0247_ $$2ISSN$$a1522-8517
000289304 0247_ $$2ISSN$$a1523-5866
000289304 037__ $$aDKFZ-2024-00699
000289304 041__ $$aEnglish
000289304 082__ $$a610
000289304 1001_ $$00000-0002-3216-8452$$aObrecht-Sturm, Denise$$b0
000289304 245__ $$aTreatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment.
000289304 260__ $$aOxford$$bOxford Univ. Press$$c2024
000289304 3367_ $$2DRIVER$$aarticle
000289304 3367_ $$2DataCite$$aOutput Types/Journal article
000289304 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1725632100_3122
000289304 3367_ $$2BibTeX$$aARTICLE
000289304 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289304 3367_ $$00$$2EndNote$$aJournal Article
000289304 500__ $$a2024 Sep 5;26(9):1712-1722
000289304 520__ $$aThis study aims at clarifying the impact of persistent residual lesions following first-line treatment for pediatric medulloblastoma.Data on 84 pediatric patients with medulloblastoma and persistent residual lesions on centrally reviewed MRI at the end of first-line therapy were analyzed.Twenty patients (23.8%) had residual lesions in the tumor bed (R+/M0), 51 (60.7%) had distant lesions (R0/M+) and 13 (15.5%) had both (R+/M+). Overall response to first-line therapy was minor or partial (≥25% reduction, MR/PR) for 64 (76.2%) and stable disease (SD) for 20 patients (23.8%). Five-year post-primary-treatment progression-free (pptPFS) and overall survival (pptOS) were superior after MR/PR (pptPFS: 62.5±7.0%[MR/PR] vs. 35.9±12.8%[SD], p=0.03; pptOS: 79.7±5.9[MR/PR] vs. 55.5±13.9[SD], p=0.04). Further, R+/M+ was associated with a higher risk for progression (5-year pptPFS: 22.9±17.9%[R+,M+] vs. 72.4±12.0%[R+,M0]; p=0.03). Watch-and-wait was pursued in 58 patients, while n=26 received additional treatments (chemotherapy only, n=19; surgery only, n=2; combined, n=3; valproic acid, n=2), and their outcomes were not superior to watch-and-wait (5-year pptPFS: 58.5±7.7% vs. 51.6±10.7% p=0.71; 5-year pptOS: 76.3±6.9% vs. 69.8±9.7%, p=0.74). For the whole cohort, five-year pptPFS by molecular subgroup (58 cases) were WNT: 100%, SHH: 50.0±35.4%, Group-4, 52.5±10.5, Group-3 54.2±13.8%; (p=0.08).Overall response and extent of lesions can function as surrogate parameters to predict outcomes in pediatric MB patients with persistent lesions after first-line therapy. Especially in case of solitary persistent medulloblastoma MRI lesion, additional therapy was not beneficial. Therefore, treatment response, extent/kind of residual lesions and further diagnostic information needs consideration for indication of additional treatments for persisting lesions.
000289304 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000289304 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289304 650_7 $$2Other$$aMRI
000289304 650_7 $$2Other$$achildren
000289304 650_7 $$2Other$$amedulloblastoma
000289304 650_7 $$2Other$$apersistent residual disease
000289304 7001_ $$aSchömig, Lena$$b1
000289304 7001_ $$00000-0003-3302-2719$$aMynarek, Martin$$b2
000289304 7001_ $$aBison, Brigitte$$b3
000289304 7001_ $$aSchwarz, Rudolf$$b4
000289304 7001_ $$aPietsch, Torsten$$b5
000289304 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b6$$udkfz
000289304 7001_ $$0P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aSill, Martin$$b7$$udkfz
000289304 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b8$$udkfz
000289304 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b9$$udkfz
000289304 7001_ $$aKortmann, Rolf-Dieter$$b10
000289304 7001_ $$aGerber, Nicolas U$$b11
000289304 7001_ $$avon Bueren, André O$$b12
000289304 7001_ $$aFleischhack, Gudrun$$b13
000289304 7001_ $$00000-0002-8731-1121$$aSchüller, Ulrich$$b14
000289304 7001_ $$aNussbaumer, Gunther$$b15
000289304 7001_ $$aBenesch, Martin$$b16
000289304 7001_ $$aRutkowski, Stefan$$b17
000289304 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae071$$gp. noae071$$n9$$p1712-1722$$tNeuro-Oncology$$v26$$x1522-8517$$y2024
000289304 909CO $$ooai:inrepo02.dkfz.de:289304$$pVDB
000289304 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000289304 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000289304 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000289304 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000289304 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000289304 9141_ $$y2024
000289304 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000289304 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000289304 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000289304 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000289304 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000289304 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000289304 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000289304 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000289304 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000289304 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000289304 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000289304 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000289304 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000289304 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x2
000289304 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x3
000289304 980__ $$ajournal
000289304 980__ $$aVDB
000289304 980__ $$aI:(DE-He78)B062-20160331
000289304 980__ $$aI:(DE-He78)HD01-20160331
000289304 980__ $$aI:(DE-He78)B360-20160331
000289304 980__ $$aI:(DE-He78)B300-20160331
000289304 980__ $$aUNRESTRICTED